Biologics and JAK inhibitors for the Dermatology SCE: mechanisms, screening and adverse effects

2026-08-02

A friendly, high-yield revision guide to the biologics and JAK inhibitors that appear in the Dermatology SCE: cytokine targets and mechanisms, baseline screening and infection risk, vaccination principles, class-specific adverse effects, MHRA JAK risk groups, and how to pick the right agent in psoriasis and atopic eczema vignettes.

Illustration of a monoclonal antibody, cytokine signalling pathways and treatment screening

Biologics and JAK inhibitors are among the most reliably examined topics in the Dermatology SCE, and for good reason: they combine immunology, pharmacology, safety screening and clinical decision making in a way that lends itself perfectly to single best answer questions. The good news is that most of the marks come from a small, well-defined set of facts. If you can match each drug to its cytokine target, recall the baseline screening you do before starting treatment, and remember the class-specific adverse effects and cautions, you will handle the majority of vignettes with confidence.

This guide walks through the mechanisms, the screening and vaccination principles, the distinctive adverse effects of each class, the MHRA safety warnings for JAK inhibitors, and how examiners frame psoriasis and atopic eczema vignettes. The emphasis throughout is on recurring patterns, so that when you meet an unfamiliar drug name you can still reason your way to the answer.

Why this topic is so heavily examined

Systemic therapy for inflammatory skin disease has changed enormously, and the SCE reflects contemporary practice. Questions test whether you understand the rationale for targeting specific cytokines, whether you screen patients safely, and whether you can recognise the adverse effects each class produces. Rather than memorising isolated trivia, build a mental map that links target, mechanism, screening and safety, because examiners often test the connections between them rather than any single fact in isolation.

Cytokine targets and mechanisms

The first job is to map each biologic to the cytokine or receptor it blocks. In psoriasis, the disease is driven largely by the IL-23 and IL-17 axis, so agents that interrupt this pathway are highly effective. In atopic eczema, type 2 inflammation driven by IL-4 and IL-13 is central, so the biologics used there target that axis. Keeping the two disease pathways separate is the single most useful thing you can do for vignette selection.

TNF inhibitors (adalimumab, etanercept, infliximab, certolizumab pegol) block tumour necrosis factor alpha. They were the first biologics used in psoriasis but are less specific to the psoriasis pathway than newer agents. Certolizumab pegol is notable for minimal placental transfer, making it a useful option in pregnancy.
IL-12/23 inhibition is the mechanism of ustekinumab, which binds the shared p40 subunit of both interleukin 12 and interleukin 23. Because it targets a subunit common to two cytokines it has a broad effect on the pathway.
IL-23 inhibitors (guselkumab, risankizumab, tildrakizumab) bind the p19 subunit and so target IL-23 more selectively than ustekinumab. IL-23 sits upstream of the IL-17 producing cells, which explains their durable efficacy in psoriasis.
IL-17 inhibitors work at the effector end of the pathway. Secukinumab and ixekizumab bind IL-17A. Bimekizumab is distinctive because it inhibits both IL-17A and IL-17F, giving dual cytokine blockade. Brodalumab is different again: it targets the IL-17 receptor A (IL-17RA) rather than the cytokine itself, blocking signalling from multiple IL-17 family members.
IL-4 receptor alpha blockade is the mechanism of dupilumab, which binds the shared IL-4 receptor alpha subunit and thereby inhibits signalling of both IL-4 and IL-13, the central cytokines of type 2 inflammation in atopic eczema.
IL-13 inhibitors (tralokinumab, lebrikizumab) neutralise IL-13 more selectively, offering another route to dampening type 2 inflammation in atopic eczema.
JAK inhibitors (for example baricitinib, upadacitinib and abrocitinib for atopic eczema) are small molecules that block Janus kinase enzymes. By interrupting JAK-STAT signalling they reduce transmission of signals from many cytokine receptors at once, giving broad immunomodulation that explains both their efficacy and their wider safety profile.

Baseline screening before starting treatment

Every vignette about starting a biologic or JAK inhibitor is really a question about safe prescribing. Before treatment you take a careful history and examination looking for infection risk, malignancy, cardiovascular risk factors and pregnancy planning, then arrange baseline investigations and screen for latent infection. The exact panel depends on the agent and local policy, so the safe answer in an exam is usually to follow the summary of product characteristics (SmPC) and local protocol rather than a rigid universal rule.

History and examination should cover current and recurrent infections, tuberculosis exposure, malignancy, demyelinating disease and heart failure (relevant to TNF inhibitors), venous thromboembolism and cardiovascular risk, and pregnancy or breastfeeding plans.
Baseline bloods commonly include a full blood count (FBC), urea and electrolytes (U&E) and liver function tests (LFT), helping detect cytopenias or renal and hepatic problems that may influence the choice of agent or subsequent monitoring.
Infection risk assessment is central. Screen for latent tuberculosis and for hepatitis B and hepatitis C in line with local policy and the specific agent, because different drugs carry different reactivation risks. HIV testing may also be appropriate.
Tuberculosis screening typically uses an interferon gamma release assay and a chest radiograph, with the precise approach set by local infection policy. Latent TB should be identified and managed before immunosuppression begins.

Vaccination principles

Vaccination is a predictable exam theme because it combines immunology with practical safety. The guiding principle is that patients who are immunosuppressed, or about to become so, should have their vaccination status reviewed and updated wherever possible before treatment starts. Live vaccines are generally avoided during significant immunosuppression, whereas inactivated vaccines are safe but may produce a weaker response.

Review and update vaccinations before starting where the clinical situation allows, so that any live vaccines can be given ahead of immunosuppression.
Avoid live vaccines during treatment with biologics or JAK inhibitors that cause meaningful immunosuppression, in line with Green Book guidance.
Offer inactivated vaccines such as the annual influenza vaccine and pneumococcal vaccination, recognising that the immune response may be attenuated.
Follow the Green Book and local policy for specific timing, because recommendations differ between agents and are periodically updated.

Distinctive class adverse effects and cautions

Adverse effects are where the SCE separates candidates who have memorised drug names from those who understand the classes. Each class has a signature safety concern, and vignettes are often built around recognising it. Focus on the distinctive associations below rather than every possible side effect.

TNF inhibitors: reactivation of latent tuberculosis and hepatitis B, increased risk of serious infection, caution in moderate to severe heart failure, and a recognised association with demyelinating disease and drug-induced lupus.
IL-12/23 and IL-23 inhibitors: generally well tolerated, with infection risk as the main consideration. They are often the agents examiners contrast favourably against classes with more specific hazards.
IL-17 inhibitors: a characteristic increase in mucocutaneous candidiasis because IL-17 is important in antifungal mucosal defence, and caution in inflammatory bowel disease, in whom IL-17 blockade may worsen bowel inflammation. This IBD caution is a favourite exam point.
IL-4 receptor alpha and IL-13 inhibitors: conjunctivitis is a distinctive and frequently examined adverse effect of dupilumab, along with injection site reactions. The type 2 targeted mechanism means these agents do not carry the same broad infection profile as pathway-wide immunosuppressants.
JAK inhibitors: a broad small molecule immunomodulatory profile brings a wider set of cautions, including serious infections (notably herpes zoster reactivation), cytopenias, deranged lipids, and the cardiovascular, thromboembolic, malignancy and mortality signals summarised in the MHRA safety warning below.

MHRA JAK inhibitor risk groups

The MHRA has issued specific measures to reduce the risks of major cardiovascular events, malignancy, venous thromboembolism, serious infections and increased mortality with JAK inhibitors. This is high-yield, because it defines groups of patients in whom JAK inhibitors should be used only if no suitable alternative exists. Knowing who falls into the higher risk category will often let you eliminate a JAK inhibitor answer immediately.

People aged 65 years and over are identified as a higher risk group in the MHRA guidance.
Current or long-term smokers (past or present) fall into the higher risk category.
Patients with increased cardiovascular risk, for example those with a history of atherosclerotic cardiovascular disease or other cardiovascular risk factors.
Patients with increased risk of malignancy should be considered carefully, as JAK inhibitors carry a malignancy signal.
Patients with risk factors for venous thromboembolism, in whom the thrombotic risk is a specific concern. In all of these groups, use a JAK inhibitor only if no suitable alternative is available, and use the lowest effective dose, in keeping with the MHRA advice.

Choosing an agent: psoriasis and atopic eczema vignettes

Vignette selection questions ask you to match a patient to the most appropriate biologic, but they rarely reward memorising a single universal first-line agent. In practice the choice depends on the patient, comorbidities, contraindications, preference and local commissioning, and the best answer is usually the agent whose profile fits the clues in the stem. Read for the distinctive feature the examiner has planted.

Psoriasis with concomitant inflammatory bowel disease: be cautious with IL-17 inhibitors, which may worsen IBD, and consider an agent whose profile is more favourable in that setting.
Psoriasis in a patient planning pregnancy: certolizumab pegol is often highlighted because of its minimal placental transfer, so a stem emphasising pregnancy is steering you towards it.
Psoriasis with significant psoriatic arthritis: an agent with good joint as well as skin efficacy is favoured, which is a clue often built into the stem.
Atopic eczema needing a biologic: dupilumab targets IL-4 receptor alpha, with tralokinumab and lebrikizumab targeting IL-13; watch for conjunctivitis as a distinctive dupilumab adverse effect.
Atopic eczema where a JAK inhibitor is proposed: check the patient against the MHRA risk groups before selecting a JAK inhibitor over a biologic.
Heart failure or demyelinating disease in the history: TNF inhibitors carry specific cautions here, so the stem may be pushing you away from them.

Notice that in every case the answer flows from matching a patient feature to a drug property. That is the reasoning the SCE rewards, and it is far more reliable than recalling a rigid ranking of agents. When unsure, return to the disease pathway (IL-23 and IL-17 for psoriasis, IL-4 and IL-13 for atopic eczema) and filter the remaining options by the safety clues in the stem.

Common exam traps to avoid

Confusing the IL-17 agents: remember IL-17A only (secukinumab, ixekizumab), dual IL-17A and IL-17F (bimekizumab), and receptor blockade IL-17RA (brodalumab).
Forgetting the IBD caution with IL-17 inhibitors, which is one of the most frequently tested safety points.
Overlooking conjunctivitis as the signature dupilumab adverse effect.
Quoting a fixed monitoring schedule as if it applied to every drug; the safe position is to follow the SmPC and local protocol.
Ignoring the MHRA JAK risk groups when a JAK inhibitor is offered to an older patient, a smoker, or someone with cardiovascular, malignancy or thromboembolic risk.
Assuming a single universal first-line biologic; the correct answer depends on the patient features in the stem.

How this fits your wider revision

Biologics and JAK inhibitors are one of several high-return domains in the Dermatology SCE, and the reasoning you build here transfers to other pharmacology and safety questions. For a broader view of where to spend your time, see our guide to the highest yield topics for the Dermatology SCE. To sharpen the technique of matching patient clues to the best answer, the approach in how to approach SBA questions in the Dermatology SCE applies particularly well to the vignette selection questions here.

Work through the cytokine map, the screening and vaccination principles, the class-specific adverse effects and the MHRA JAK risk groups until you can reproduce them from memory. Do that, and the biologics questions should feel like some of the most predictable marks on the paper.

Sources & further reading

For educational use only. Check current official guidance.

Start 25 free questions